Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Oncogenomics
  • Published:

Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma

Oncogene volume 23, pages 9148–9154 (2004)Cite this article

Abstract

Deletions of the 3p arm have been detected in various solid tumors, but no study to date has investigated this deletion in diffuse large B-cell lymphoma (DLBCL). Recently, we demonstrated that 3p14.2 was deleted in approximately 30% of DLBCL cases by use of a genome-wide array-comparative genomic hybridization (CGH). For a more detailed examination of the genomic losses at 3p14.2, here we made use of contig BAC array for 3p14.2, and found that 12 DLBCL samples displayed losses. All of the deleted regions were located within the fragile histidine triad (FHIT) gene, and the most frequent region of loss was mapped to 0.4 Mbp of the region encompassing the introns 4 and 5 and exon 5 of the FHIT gene. Concomitant analysis of transcripts showed that the FHIT gene was aberrantly transcribed in 31% of the DLBCL samples examined and that the lost exons of the aberrant transcripts were correlated with genomic deletions. These findings indicate that (1) loss of genomic material at 3q14.2 is responsible for exon losses of the FHIT gene, and (2) genomic loss of the FHIT gene is one of the causes of the generation of aberrant transcripts.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Albitar M, Manshouri T, Gidel C, Croce C, Kornblau S, Pierce S and Kantarjian HM . (2001). Leuk. Res., 25, 859–864.

  • Barth TF, Dohner H, Werner CA, Stilgenbauer S, Schlotter M, Pawlita M, Lichter P, Moller P and Bentz M . (1998). Blood, 91, 4321–4330.

  • Berglund M, Enblad G, Flordal E, Lui WO, Backlin C, Thunberg U, Sundstrom C, Roos G, Allander SV, Erlanson M, Rosenquist R, Larsson C and Lagercrantz S . (2002). Mod. Pathol., 15, 807–816.

  • Chen PM, Yang MH, Hsiao LT, Yu IT, Chu CJ, Chao TC, Yen CC, Wang WS, Chiou TJ and Liu JH . (2004). Oncol. Rep., 11, 349–356.

  • Chirgwin JM, Przybyla AE, MacDonald RJ and Rutter WJ . (1979). Biochemistry, 18, 5294–5299.

  • Cigudosa JC, Parsa NZ, Louie DC, Filippa DA, Jhanwar SC, Johansson B, Mitelman F and Chaganti RS . (1999). Genes Chromosomes Cancer, 25, 123–133.

  • Dave BJ, Nelson M, Pickering DL, Chan WC, Greiner TC, Weisenburger DD, Armitage JO and Sanger WG . (2002). Cancer Genet. Cytogenet., 132, 125–132.

  • Druck T, Hadaczek P, Fu TB, Ohta M, Siprashvili Z, Baffa R, Negrini M, Kastury K, Veronese ML, Rosen D, Rothstein J, McCue P, Cotticelli MG, Inoue H, Croce CM and Huebner K . (1997). Cancer Res., 57, 504–512.

  • Ferrer M, Lopez-Borges S and Lazo PA . (1999). Mol. Carcinog., 25, 55–63.

  • Fong LY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, Mancini R, Siprashvili Z, Ottey M, Martin SE, Druck T, McCue PA, Croce CM and Huebner K . (2000). Proc. Natl. Acad. Sci. USA, 97, 4742–4747.

  • Gemma A, Hagiwara K, Ke Y, Burke LM, Khan MA, Nagashima M, Bennett WP and Harris CC . (1997). Cancer Res., 57, 1435–1437.

  • Hallas C, Albitar M, Letofsky J, Keating MJ, Huebner K and Croce CM . (1999). Clin. Cancer Res., 5, 2409–2414.

  • Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA and Bloomfield CD . (1999). J. Clin. Oncol., 17, 3835–3849.

  • Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B and Gatter KC . (1994). Blood, 84, 1361–1392.

  • Hendricks DT, Taylor R, Reed M and Birrer MJ . (1997). Cancer Res., 57, 2112–2115.

  • Huebner K and Croce CM . (2001). Nat. Rev. Cancer, 1, 214–221.

  • Iwai T, Yokota S, Nakao M, Nakazawa N, Taniwaki M, Kimura T, Sonoda Y, Kaneko H, Okuda T, Azuma H, Oka T, Takeda T, Watanabe A, Kikuta A, Asami K, Sekine I, Matsushita T, Tsuchiya T, Mimaya J, Koizumi S, Ohta S, Miyake M, Takaue Y, Iwai A and Fujimoto T . (1998). Cancer Res., 58, 5182–5187.

  • Karnan S, Tagawa H, Suzuki R, Suguro M, Yamaguchi M, Okamoto M, Morishima Y, Nakamura S and Seto M . (2004). Genes Chromosomes Cancer, 39, 77–81.

  • Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, de Jong D, Maartense E, Schuuring E and Kluin PM . (1998). Blood, 92, 3152–3162.

  • Matsuyama A, Shiraishi T, Trapasso F, Kuroki T, Alder H, Mori M, Huebner K and Croce CM . (2003). Proc. Natl. Acad. Sci. USA, 25, 14988–14993.

  • Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K and Croce CM . (1996). Cancer Res., 56, 3173–3179.

  • Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P and Druck T . (1996). Cell, 84, 587–597.

  • Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, Yoshida Y and Seto M . (2004). Cancer Res., 64, 3087–3095.

  • Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K and Croce CM . (2002). Lancet Oncol., 3, 748–754.

  • Peters UR, Hasse U, Oppliger E, Tschan M, Ong ST, Rassool FV, Borisch B, Tobler A and Fey MF . (1999). Oncogene, 18, 79–85.

  • Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW and Albertson DG . (1998). Nat. Genet., 20, 207–211.

  • Smeets DF, Scheres JM and Hustinx TW . (1986). Hum. Genet., 72, 215–220.

  • Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Dohner H, Cremer T and Lichter P . (1997). Genes Chromosomes Cancer, 20, 399–407.

  • Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K and Croce CM . (1996). Cell, 85, 17–26.

  • Tagawa H, Tsuzuki S, Suzuki R, Karnan S, Ota A, Kameoka Y, Suguro M, Matsuo K, Yamaguchi M, Okamoto M, Morishima Y, Nakamura S and Seto M . (2004). Cancer Res., 64, 5948–5955.

  • Tweeddale ME, Lim B, Jamal N, Robinson J, Zalcberg J, Lockwood G, Minden MD and Messner HA . (1987). Blood, 69, 1307–1314.

  • Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K and Croce CM . (1996). Proc. Natl. Acad. Sci. USA, 93, 9770–9775.

  • Wessendorf S, Schwaenen C, Kohlhammer H, Kienle D, Wrobel G, Barth TF, Nessling M, Moller P, Dohner H, Lichter P and Bentz M . (2003). Oncogene, 22, 1425–1429.

Download references

Acknowledgements

We are grateful to Drs Wen-Lin Kuo and Joe Gray at the University of California, San Francisco, for kindly providing us with a detailed protocol for array CGH. The outstanding technical assistance of Mss H Suzuki and Y Kasugai is also very much appreciated. This work was supported in part by a Grant-in-Aid for the Second-Term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labor and Welfare, a Grant-in-aid for Science on Primary Areas (Cancer Research) from the Ministry of Education, Culture, Sports, Science and Technology and a Grant-in-Aid for Cancer Research from the Princess Takamatsu Cancer Research Fund.

Author information

Authors and Affiliations

  1. Division of Molecular Medicine, Aichi Cancer Center Research Institute, Aichi, Japan

    Yoshihiro Kameoka, Hiroyuki Tagawa, Shinobu Tsuzuki, Sivasundaram Karnan, Akinobu Ota, Miyuki Suguro, Ritsuro Suzuki & Masao Seto

  2. Second Department of Internal Medicine, Mie University School of Medicine, Japan

    Motoko Yamaguchi

  3. Department of Hematology and Chemotherapy, Aichi Cancer Center, Aichi, Japan

    Yasuo Morishima

  4. Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Aichi, Japan

    Shigeo Nakamura

Authors
  1. Yoshihiro Kameoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroyuki Tagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shinobu Tsuzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sivasundaram Karnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akinobu Ota
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Miyuki Suguro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ritsuro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Motoko Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yasuo Morishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shigeo Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masao Seto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masao Seto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kameoka, Y., Tagawa, H., Tsuzuki, S. et al. Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma. Oncogene 23, 9148–9154 (2004). https://doi.org/10.1038/sj.onc.1208136

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208136

Keywords

This article is cited by

Search

Advanced search

Quick links